Ian D. Pavord
University of Oxford
AirwayInternal medicineRandomized controlled trialIntensive care medicinePhysical therapyImmunologyPlaceboAsthmaSputumCOPDExacerbationEosinophilChronic coughEosinophilicExhaled nitric oxidePopulationIn patientAnesthesiaMedicineGastroenterology
Publications 824
#1Alvar Agusti (University of Barcelona)H-Index: 117
#2Neil Barnes (QMUL: Queen Mary University of London)H-Index: 70
Last. John Oppenheimer (RU: Rutgers University)H-Index: 35
view all 15 authors...
Abstract null null Asthma and chronic obstructive pulmonary disease (COPD) are two prevalent chronic airways diseases. Both are complex and heterogeneous. Traditionally, clinical guidelines have advocated a stepwise approach to pharmacotherapy of asthma and COPD, but there is increasing realization that both require a more personalized and precise management approach. To this end, a management strategy based on the so-called Treatable Traits has been proposed. Emerging evidence suggests that thi...
#1Michael E. WechslerH-Index: 55
#2Linda B. FordH-Index: 8
Last. Yuji Tohda (Kindai University)H-Index: 22
view all 27 authors...
Summary null null Background null Clinical trials have shown treatment benefits of dupilumab in patients with uncontrolled asthma for up to 1 year. This study aimed to evaluate the long-term safety and efficacy of dupilumab in patients with moderate-to-severe asthma, as data for extended treatment with dupilumab beyond 1 year are not available. null null null Methods null TRAVERSE was an open-label extension study in 362 hospitals and clinical centres across 27 countries that assessed the safety...
#1John Busby ('QUB': Queen's University Belfast)H-Index: 15
#2John G. MatthewsH-Index: 8
Last. Douglas C. Cowan (NHS Greater Glasgow and Clyde)H-Index: 13
view all 24 authors...
Background null Understanding why patients with severe asthma do not follow healthcare provider (HCP) advice to adjust treatment is critical to achieving personalised disease management. null Methods null We reviewed patient choice to follow HCP advice to adjust asthma treatment in a randomised, controlled, single-blind (study participant), multi-centre, parallel group 48-week clinical study comparing biomarker directed treatment adjustment to standard care in severe asthma. null Results null Of...
#1Jonathan Youngs (St George's, University of London)H-Index: 3
#2Nicholas M. Provine (University of Oxford)H-Index: 7
Last. Wentao Chen (University of Oxford)H-Index: 4
view all 34 authors...
Prior studies have demonstrated that immunologic dysfunction underpins severe illness in COVID-19 patients, but have lacked an in-depth analysis of the immunologic drivers of death in the most critically ill patients. We performed immunophenotyping of viral antigen-specific and unconventional T cell responses, neutralizing antibodies, and serum proteins in critically ill patients with SARS-CoV-2 infection, using influenza infection, SARS-CoV-2-convalescent health care workers, and healthy adults...
#1Andrew Bush (Imperial College London)H-Index: 114
#2Ian D. Pavord (University of Oxford)H-Index: 117
Airway diseases were initially described by nonspecific patterns of symptoms, for example “dry and wheezy” and “wet and crackly”. The model airway disease is cystic fibrosis, which has progressed from nonspecific reactive treatments such as antibiotics for airway infection to molecular sub-endotype, proactive therapies with an unequivocal evidence base, early diagnosis, and biomarkers of treatment efficacy. Unfortunately, other airway diseases lag behind, not least because nonspecific umbrella l...
1 CitationsSource
#1Ian D. Pavord (University of Oxford)H-Index: 117
#2Elisabeth H. Bel (UvA: University of Amsterdam)H-Index: 69
Last. Florence Roufosse (ULB: Université libre de Bruxelles)H-Index: 30
view all 13 authors...
Effective treatment of inflammatory diseases is often challenging owing to their heterogeneous pathophysiology. Understanding of the underlying disease mechanisms is improving and it is now clear that eosinophils play a complex pathophysiological role in a broad range of type 2 inflammatory diseases. Standard of care for these conditions often still includes oral corticosteroids (OCS) and/or cytotoxic immune therapies, which are associated with debilitating side effects. Selective, biological eo...
#1Rupert Jones (University of Plymouth)H-Index: 28
#2Andrew K. DavisH-Index: 32
Last. Jennifer K Quint (NIH: National Institutes of Health)H-Index: 30
view all 23 authors...
Acknowledgments Other members of the Platform C19 steering committee consist of Sir Prof Lewis Ritchie, OBE from the University of Aberdeen, Steve Davis from Interface Clinical Services, Dr Samantha Walker from Asthma UK & British Lung Foundation, Prof Stephen Holgate from the University of Southampton and the Medical Research Council, and Sue Beacroft from Open Vie/Harvey Walsh and OPCRD-NEXUS. We wish to acknowledge our GP Partner Practices: Alnwick Medical Group, Guide Post Medical Group, Pri...
#1Simon CouillardH-Index: 6
#2Annette Laugerud (Genzyme)
Last. Ian D. Pavord (University of Oxford)H-Index: 117
view all 7 authors...
Reduction of the risk of asthma attacks is a major goal of current asthma management. We propose to derive a risk scale predicting asthma attacks based on the blood eosinophil count and exhaled nitric oxide (FeNO). Biomarker-stratified trial-level attack rates were extracted and pooled from the control arms of the Novel START, CAPTAIN, QUEST, Benralizumab Phase 2b, PATHWAY, STRATOS 1-2 and DREAM trials (n=3051). These were used to derive rate ratios and the predicted asthma attack rate for diffe...
2 CitationsSource
#1Simon Couillard (Université de Sherbrooke)H-Index: 6
#2David A. Jackson ('KCL': King's College London)H-Index: 156
Last. Ian D. Pavord (University of Oxford)H-Index: 117
view all 4 authors...
A 56-year-old man has difficult-to-control asthma and a history of four exacerbations in the prior 12 months despite high-dose inhaled corticosteroids (ICS) and additional controller therapies. Is he suitable for more advanced therapeutic options? We review the clinical assessment of a patient with suspected severe asthma and discuss factors contributing to poor asthma control and how biomarkers assist in disease investigation and stratification. The key components of our multidisciplinary appro...
2 CitationsSource
#1Timothy S.C. Hinks (NIHR: National Institute for Health Research)H-Index: 23
#2Lucy Cureton (University of Oxford)H-Index: 1
Last. Maisha Jabeen (NIHR: National Institute for Health Research)H-Index: 3
view all 22 authors...
Summary null Background null The antibacterial, anti-inflammatory, and antiviral properties of azithromycin suggest therapeutic potential against COVID-19. Randomised data in mild-to-moderate disease are not available. We assessed whether azithromycin is effective in reducing hospital admission in patients with mild-to-moderate COVID-19. null Methods null This prospective, open-label, randomised superiority trial was done at 19 hospitals in the UK. We enrolled adults aged at least 18 years prese...
3 CitationsSource